Brian Foard — Global Business Unit Head, Specialty Care:
“I think from an environment standpoint, the Inflation Reduction Act, there’s a couple of things in there. And as we’ve said before, our position is, it’s not really good for innovation just in general, the Inflation Reduction Act.”
All entries for: Neurological Diseases
October 25, 2024
Sanofi
Negative Outlook
Paris, France
50,001+ employees
50001+ employees
Disease Area: Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 8, 2023
Biogen
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
“The IRA’s drug pricing controls and Medicare redesign may have an adverse impact on our sales (particularly for our products that are more substantially reliant on Medicare reimbursement), our business and our results of operations. However, the degree of impact from this legislation on our business depends on a number of implementation decisions. We will continue to assess as further information becomes available.”
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
November 7, 2023
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
“It is unclear how the IRA will be implemented. We further cannot predict with certainty what impact the IRA or any other federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition. There may be additional Congressional and administrative efforts to address drug pricing.”
Disease Area: Neurological Diseases
Drug Type: Biologic
October 1, 2023
Cerevel Therapeutics
Negative Outlook
Cambridge, MA
201-500 employees
201-500 employees
“The effect of IRA on our business and the healthcare industry in general is not yet fully known. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenue generated from the sale of any approved products”
Disease Area: Neurological Diseases
Drug Type: Small Molecule
August 7, 2023
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic
August 2, 2023
Cerevel Therapeutics
Negative Outlook
Cambridge, MA
201-500 employees
201-500 employees
Disease Area: Neurological Diseases
Drug Type: Small Molecule
July 25, 2023
Biogen
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
May 3, 2023
Cerevel Therapeutics
Negative Outlook
Cambridge, MA
201-500 employees
201-500 employees
Disease Area: Neurological Diseases
Drug Type: Small Molecule
May 2, 2023
Sage Therapeutics
Negative Outlook
Cambridge, MA
501-1,000 employees
501-1000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic
April 25, 2023
Biogen
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Neurological Diseases
Drug Type: Biologic, Small Molecule
